

# 25 - References

## References

### Bipolar disorder CHAPTER 2 References

1. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? *Cell Mol Life Sci* 2007; 64:2090–2103.
2. Natale G, et al. Valproate and lithium: old drugs for new pharmacological approaches in brain tumors? *Cancer Lett* 2023; 560:216125.
3. Gervain J, et al. Valproate reopens critical-period learning of absolute pitch. *Front Syst Neurosci* 2013; 7:1–11.
4. Fisher C, et al. Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder? *Psychiatric Bulletin* 2003; 27:446–448.
5. Wassef AA, et al. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions. *Am J Psychiatry* 2005; 162:330–339.
6. SANOFI. Summary of product characteristics. Epilim Chrono (valproic acid, sodium valproate) 500mg. 2024 (last accessed October 2024); <https://www.medicines.org.uk/emc/medicine/6779>.
7. Delage C, et al. Valproate, divalproex, valpromide: are the differences in indications justified? *Biomed Pharmacother* 2023; 158:114051.
8. Bowden CL, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. *JAMA* 1994; 271:918–924.
9. Freeman TW, et al. A double-blind comparison of valproate and lithium in the treatment of acute mania. *Am J Psychiatry* 1992; 149:108–111.
10. Nasrallah HA, et al. Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. *J Affect Disord* 2006; 95:69–78.
11. Hirschfeld RM, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. *J Clin Psychiatry* 2010; 71:426–432.
12. Bowden C, et al. A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. *Int Clin Psychopharmacol* 2008; 23:254–262.
13. Pope HG, Jr, et al. Valproate in the treatment of acute mania. A placebo-controlled study. *Arch Gen Psychiatry* 1991; 48:62–68.
14. Novick D, et al. Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study. *Pharmacopsychiatry* 2009; 42:145–152.

15. Cipriani A, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. *Lancet* 2011; 378:1306–1315.
16. Kishi T, et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. *Mol Psychiatry* 2022; 27:1136–1144.
17. Hsu TW, et al. Variability and efficacy in treatment effects on manic symptoms with lithium, anticonvulsants, and antipsychotics in acute bipolar mania: a systematic review and meta-analysis. *EClinicalMedicine* 2022; 54:101690.
18. Smith LA, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. *J Affect Disord* 2010; 122:1–9.
19. Bahji A, et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. *J Affect Disord* 2020; 269:154–184.
20. Strawbridge R, et al. A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder. *Acta Psychiatr Scand* 2022; 146:290–311.
21. Calabrese JR, et al. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. *Am J Psychiatry* 1990; 147:431–434.
22. Tohen M, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. *Am J Psychiatry* 2003; 160:1263–1271.
23. Suppes T, et al. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: post hoc analyses of 47-week data. *J Affect Disord* 2005; 89:69–77.
24. Bowden CL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. *Arch Gen Psychiatry* 2000; 57:481–489.
25. Calabrese JR, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. *Am J Psychiatry* 2005; 162:2152–2161.
26. Geddes JR, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. *Lancet* 2010; 375:385–395.
27. Marcus R, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. *Bipolar Disord* 2011; 13:133–144.
28. Nestsiarovich A, et al. Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials. *Eur Neuropsychopharmacol* 2022; 54:75–89.
29. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]. 2014 (last updated December 2023, last accessed October 2024); <https://www.nice.org.uk/guidance/cg185>.
30. National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance. Clinical guideline [CG192]. 2014 (last updated February 2020, last accessed October 2024); <https://www.nice.org.uk/guidance/cg192>.
31. Cipriani A, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. *Cochrane Database Syst Rev* 2013; 10:CD003196.

32. Lindenmayer JP, et al. Use of sodium valproate in violent and aggressive behaviors: a critical review. *J Clin Psychiatry* 2000; 61:123-128.

294 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 2 33. Citrome L, et al. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. *Int Clin Psychopharmacol* 2007; 22:356-362. 34. Gobbi G, et al. Efficacy of topiramate, valproate, and their combination on aggression/agitation behavior in patients with psychosis. *J Clin Psychopharmacol* 2006; 26:467-473. 35. Aliyev NA, et al. Valproate (depakine--chronon) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. *Eur Psychiatry* 2008; 23:109-114. 36. Watson A, et al. Valproic acid use is associated with diminished risk of contracting COVID-19, and diminished disease severity: epidemiologic and in vitro analysis reveal mechanistic insights. *PLoS One* 2024; 19:e0307154. 37. Haymond J, et al. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder? *Ther Drug Monit* 2010; 32:19-29. 38. Allen MH, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. *Am J Psychiatry* 2006; 163:272-275. 39. Taylor D, et al. Doses of carbamazepine and valproate in bipolar affective disorder. *Psychiatric Bulletin* 1997; 21:221-223. 40. Krishna MBN, et al. Total valproate versus free valproate in therapeutic drug monitoring for bipolar disorder: a cross-sectional study. *Asia Pac Psychiatry* 2024; 16:e12555. 41. Segura-Bruna N, et al. Valproate--induced hyperammonemic encephalopathy. *Acta Neurol Scand* 2006; 114:1-7. 42. El-Khatib F, et al. Valproate, weight gain and carbohydrate craving: a gender study. *Seizure* 2007; 16:226-232. 43. Zadikoff C, et al. Movement disorders in patients taking anticonvulsants. *J Neurol Neurosurg Psychiatry* 2007; 78:147-151. 44. Ristic AJ, et al. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. *Epilepsia* 2006; 47:2183-2185. 45. Praharaj SK, et al. Valproate-associated hair abnormalities: pathophysiology and management strategies. *Hum Psychopharmacol* 2022; 37:e2814. 46. Gerstner T, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. *J Gastroenterol* 2007; 42:39-48. 47. Joffe H, et al. Valproate is associated with new-onset oligomenorrhea with hyperandrogenism in women with bipolar disorder. *Biol Psychiatry* 2006; 59:1078-1086. 48. Asghar MA, et al. Understanding the impact of valproate on male fertility: insights from preclinical and clinical meta-analysis. *BMC Pharmacol Toxicol* 2024; 25:69. 49. Garey JD, et al. Paternal valproate treatment and risk of childhood neurodevelopmental disorders: precautionary regulatory measures are insufficiently substantiated. *Birth Defects Res* 2024; 116:e2392. 50. Christensen J, et al. Valproate use during spermatogenesis and risk to offspring. *JAMA Netw Open* 2024; 7:e2414709. 51. Angus-Leppan H, et al. New valproate regulations, informed choice and seizure risk. *J Neurol* 2024; 271:5671-5686. 52. Bjornsson E. Hepatotoxicity associated with antiepileptic drugs. *Acta Neurol Scand* 2008; 118:281-290. 53. Paterno E, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. *JAMA* 2010; 303:1401-1409. 54. Gibbons RD, et al. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder. *Arch Gen Psychiatry* 2009; 66:1354-1360. 55. Arana A, et al. Suicide-related events in patients treated with antiepileptic drugs. *N Engl J Med* 2010; 363:542-551. 56. Andersohn F, et al. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. *Neurology* 2010; 75:335-340. 57. Franks MA, et al. Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. *J Psychopharmacol* 2008; 22:452-456. 58. Mbizvo GK, et al. Morbidity and mortality risks associated with valproate withdrawal in young adults with epilepsy. *Brain* 2024; 147:3426-3441. 59. National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. NICE

guideline [NG217]. 2022 (last accessed October 2024); <https://www.nice.org.uk/guidance/ng217>.

60. James L, et al. Informing patients of the teratogenic potential of mood stabilising drugs; a case notes review of the practice of psychiatrists. *J Psychopharmacol* 2007; 21:815–819. 61. James L, et al. Mood stabilizers and teratogenicity – prescribing practice and awareness amongst practising psychiatrists. *J Mental Health* 2009; 18:137–143. 62. Meador KJ, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. *N Engl J Med* 2009; 360:1597–1605. 63. Sandson NB, et al. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. *Am J Psychiatry* 2006; 163:1891–1896. 64. Fehr C, et al. Increase in serum clomipramine concentrations caused by valproate. *J Clin Psychopharmacol* 2000; 20:493–494. 65. Morris RG, et al. Clinical study of lamotrigine and valproic acid in patients with epilepsy: using a drug interaction to advantage? *Ther Drug Monit* 2000; 22:656–660. 66. Aichhorn W, et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. *Int Clin Psychopharmacol* 2006; 21:81–85. 67. Gunes A, et al. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. *Basic Clin Pharmacol Toxicol* 2007; 100:383–386. 68. Bergemann N, et al. Valproate lowers plasma concentration of olanzapine. *J Clin Psychopharmacol* 2006; 26:432–434.

---

Revision #1

Created 2026-01-04 20:14:20 UTC by Omar Ayman

Updated 2026-01-04 20:14:20 UTC by Omar Ayman